IBRX - ImmunityBio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.523B

Cash

170.5M

Avg Qtr Burn

-97.36M

Short % of Float

30.20%

Insider Ownership

77.59%

Institutional Own.

9.97%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Anktiva (N-803) + BCG Details Bladder cancer, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PD-L1 t-haNK Details Pancreatic cancer, Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Anktiva (N-803) + checkpoint inhibitors Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
hAd5-COVID-19 Details Vaccine, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.